Nerve growth factor in traumatic optic neuropathy
DOI:
https://doi.org/10.24265/horizmed.2023.v23n1.09Keywords:
nerve growth factor, visual acuity, optic nerve diseases, wounds and injuriesAbstract
Traumatic optic neuropathy (TON) is an entity associated with facial and cranial trauma, and a leading cause of blindness. It is a severe complication of craniofacial trauma that directly (DTON) or indirectly (ITON) damages the optic nerve (ON) and whose global incidence is 0.7 to 2.5 %. The objective of this study is to present the case of a patient who suffered from
TON and, at the same time, an asymmetrical bilateral condition, and was treated with nerve growth factor (NGF). This drug was the first to be discovered and demonstrate efficacy in maintaining the survival of central and peripheral neurons and facilitating their growth, differentiation and regeneration. A 13-year-old male patient attended the emergency room of Instituto Nacional de Ciencias Neurológicas and was later followed up at the Neuro-Ophthalmology Service. He was diagnosed with post-traumatic amaurosis caused by traumatic brain injury and epidural hematoma, and received two treatment cycles of NGF. After the first treatment cycle, hyporeactivity of both eyes occurred. And, at the end of the second treatment cycle, visual acuity improved significantly. NGF has been approved and marketed in China since 2015 and is a product that
has demonstrated its efficacy and safety in several clinical trials. Therefore, this study aims to make NGF a promising ITON treatment; in that sense, further clinical research is needed in this particular case.
Downloads
References
Chen B, Zhang H, Zhai Q, Li H, Wang C, Wang Y. Traumatic optic neuropathy: a review of current studies. Neurosurg Rev. 2022;45(3):1895-913.
Karimi S, Arabi A, Ansari I, Shahraki T, Safi S. A systematic literature review on traumatic optic neuropathy. J Ophthalmol. 2021;2021:5553885.
Pirouzmand F. Epidemiological trends of traumatic optic nerve injuries in the largest Canadian adult trauma center. J Craniofac Surg. 2012;23(2):516-20.
Lee V, Ford R, Xing W, Bunce C, Foot B. Surveillance of traumatic optic neuropathy in the UK. Eye (Lond). 2010;24(2):240-50.
Singman EL, Daphalapurkar N, White H, Nguyen TD, Panghat L, Chang J, et al. Indirect traumatic optic neuropathy. Mil Med Res. 2016;3:2.
Miller NR. Traumatic optic neuropathy. J Neurol Surg B Skull Base. 2021;82(1):107-15.
Wladis EJ, Aakalu VK, Sobel RK, McCulley TJ, Foster JA, Tao JP, et al. Ophthalmic technology assessment interventions for indirect traumatic optic neuropathy: A report by the American Academy of Ophthalmology. Ophthalmology. 2021;128(6):928-37.
Razeghinejad MR, Rahat F, Bagheri M. Levodopa-carbidopa may improve vision loss in indirect traumatic optic neuropathy. J Neurotrauma. 2010;27(10):1905-9.
Hai-Tang H, Ying-Yong L, Hui-Ping H. Injection site pain of mouse nervous growth factor: A review of randomized, double-blind, parallel placebo-controlled phase to III Clinical Trials. Chin J Pharmacovigilance. 2010;7(7):397-9.
Wuhanqimuge, Itakura A, Matsuki Y, Tanaka M, Arioka M. Lysophosphatidylcholine enhances NGF-induced MAPK and Akt signals through the extracellular domain of TrkA in PC12 cells. FEBS Open Bio. 2013;3(1):243-51.
Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338(17):1174-80.
Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000;107(7):1347-51.
Falsini B, Chiaretti A, Rizzo D, Piccardi M, Ruggiero A, Manni L, et al. Nerve growth factor improves visual loss in childhood optic gliomas: a randomized, double-blind, phase II clinical trial. Brain. 2016;139(2):404-14.
Zhao M, Li XY, Xu CY, Zou LP. Efficacy and safety of nerve growth factor for the treatment of neurological diseases: a meta-analysis of 64 randomized controlled trials involving 6,297 patients. Neural Regen Res. 2015;10(5):819-28.
Kanu LN, Ciolino JB. Nerve growth factor as an ocular therapy: Applications, challenges, and future directions. Semin Ophthalmol. 2021;36(4):224-31.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
